EicOsis Expanded Access Policy

EicOsis Human Health (EicOsis) is committed to developing a new therapeutic approach for patients with pain. Our goal is to provide access to our investigational therapies primarily through ongoing clinical trials.

“Expanded Access” refers to a potential pathway for a patient with an immediately life-threatening condition or serious disease to gain access to an investigational therapy outside of a clinical trial when no comparable or satisfactory alternatives exist and there is enough clinical evidence that the patient may benefit from it.

EicOsis is currently conducting Phase 1 clinical trials in healthy volunteers for EC5026, its lead drug candidate for the treatment of neuropathic pain. EicOsis believes that participation in one of its’ clinical trials is the most appropriate way to access EC5026.

At this time, EicOsis is not currently making EC5026 available on an expanded access basis. In the event EicOsis decides to consider expanded access or right to try use, EicOsis will evaluate and respond to each request that it receives on a case-by-case basis. You may find information about our ongoing clinical trials by accessing https://clinicaltrials.gov.

Consistent with the 21st Century Cures Act, EicOsis may revise this policy at any time.

If you have any questions, please reach out to us at info@eicosis.com. You can find further contact details on the Contact page of our website.